Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glycylglutamine
- Development stage
- Phase 1
- Modality
- Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
Glycylglutamine is a dipeptide composed of glycine and L-glutamine. It is used as an ingredient in amino acid solutions for parenteral nutrition due to its higher solubility and thermostability compared to free glutamine. After intravenous administration, it is rapidly hydrolyzed into glycine and glutamine in the body[2][6]. Glycylglutamine also acts as a biologically active neuropeptide derived from β-endorphin(1-31), with evidence suggesting it can attenuate morphine-induced conditioned place preference, tolerance, dependence, withdrawal symptoms, cardiovascular depression, and respiratory depression without affecting opioid analgesia[5][8]. Its precise receptor mechanism remains unidentified but does not appear to involve opioid or glycine receptors[8].
- Other names
- Gly-glnglycyl-glutamineglycyl-L-glutamine
Beyond the preview
Go deeper on glycylglutamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glycylglutamine.